Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

  • End date
    Jul 12, 2024
  • participants needed
  • sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Updated on 12 March 2022


The purpose of this study is to evaluate the safety and clinical activity of paclitaxel plus olaparib and pembrolizumab in patients with previously treated advanced Gastric Cancer (GC).

Condition Advanced Gastric Adenocarcinoma
Treatment Paclitaxel, Pembrolizumab, olaparib
Clinical Study IdentifierNCT04209686
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last Modified on12 March 2022


Yes No Not Sure

Inclusion Criteria

Age ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Must have advanced gastric or gastroesophageal cancer
Must have received and progressed on only one prior line of systemic therapy for advanced disease
Must have the presence of measurable lesion
Must agree to have a biopsy
Life expectancy of greater than 3 months
Patients must have adequate organ and marrow function defined by study - specified laboratory tests
Woman of childbearing potential must have a negative pregnancy test
Must use acceptable form of birth control while on study
Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Require any antineoplastic therapy
Require any other form of systemic or localized antineoplastic therapy
Has received prior therapy with paclitaxel or PARP inhibitor. Previous paclitaxel may be allowed if no progression on or within 6 months of receiving this drug
Hypersensitivity reaction to any paclitaxel, pembrolizumab or related compounds and/or to any of the components
Allergy to dexamethasone, diphenhydramine and famotidine
Is taking a moderate or strong CYP3A inhibitor
Has uncontrolled intercurrent acute or chronic medical illness
Has a known additional malignancy that is progressing and has required active treatment within the past 1 year
Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to study treatment
Has received prior radiotherapy within 2 weeks of start of study treatment
Has received a live vaccine within 30 days prior to the first dose of study drug
Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug
Has an active known or suspected autoimmune disease
Has a diagnosis of immunodeficiency
Prior tissue or organ allograft or allogeneic bone marrow transplantation
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
Requires daily supplemental oxygen
History of (non-infectious) pneumonitis that required steroids or has current pneumonitis
History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
Infection with HIV or hepatitis B or C at screening
Has uncontrolled infection requiring systemic therapy
Subjects unable to undergo venipuncture and/or tolerate venous access
Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
Woman who are pregnant or breastfeeding
A woman of childbearing potential (WOCBP) who has a positive urine pregnancy test within 72 hours prior to study drug initiation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note